InvestorsHub Logo
Followers 70
Posts 9531
Boards Moderated 0
Alias Born 07/17/2013

Re: None

Monday, 06/15/2020 12:29:42 PM

Monday, June 15, 2020 12:29:42 PM

Post# of 403752
$IPIX Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

April 1st - The Company is reviewing data received yesterday and anticipates more data will be forthcoming. Following discussions with researchers at the RBL, the Company will provide additional information and insight into possible joint research plans going forward. It is management’s understanding that few compounds advance to this next stage of SARS-CoV-2 research.

——————-

https://www.eurekalert.org/pub_releases/2020-06/gmu-nsa060520.php

June 5 - Aarthi Narayanan, Associate Professor, National Center for Biodefense and Infectious Diseases, received $35,000 from Innovation Pharmaceuticals, Inc., for a project in which she is examining the use of Brilacidin for the treatment of coronavirus infections.

“And there seems to be no sign of intelligent life anywhere.”